A signaling pathway that is frequently deregulated in human carcinomas and has been
explored as a therapeutic target involves the activation of the epidermal growth factor …

EGF receptor (EGFR) kinase inhibitors, including gefitinib and erlotinib, exert potent
therapeutic efficacy in non–small cell lung cancers harboring EGFR-activating mutations …

The epidermal growth-factor receptor (EGFR) tyrosine kinase inhibitor erlotinib has been
proven to be highly effective in the treatment of nonsmall cell lung cancer (NSCLC) …

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) therapy often
provides a dramatic response in lung cancer patients with EGFR mutations. In addition …

EGFR-mutated non-small cell lung cancer patients experience relapse within 1-2 years of
treatment with EGFR-inhibitors, such as erlotinib. Multiple resistance mechanisms have …

Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR)
mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and …

Background Epidermal growth factor receptor (EGFR) signaling plays an important role in
non-small cell lung cancer (NSCLC) and therapeutics targeted against EGFR have been …

Purpose Acquired resistance to erlotinib in patients with EGFR-mutant non-small cell lung
cancer can result from aberrant activation of alternative receptor tyrosine kinases, such as …

Introduction Mesenchymal status is related to “inherent resistance” to gefitinib or erlotinib in
non-small cell lung cancer without epidermal growth factor receptor (EGFR) mutations. In …

Overexpression and mutational activation of the epidermal growth factor receptor (EGFR)
plays an important role in the pathogenesis of non–small cell lung cancer (NSCLC). EGFR …